Scarica l'app Stockscreener
1.20
6.61%
-0.085
Dopo l'orario di chiusura:
1.20
Precedente Chiudi:
$1.285
Aprire:
$1.3
Volume 24 ore:
21,516
Relative Volume:
0.67
Capitalizzazione di mercato:
$10.72M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-1.692
EPS:
-0.7092
Flusso di cassa netto:
-
1 W Prestazione:
-8.40%
1M Prestazione:
-13.67%
6M Prestazione:
-33.33%
1 anno Prestazione:
-53.85%
Intervallo 1D:
$1.19
$1.30
Intervallo di 1 settimana:
$1.19
$1.338
Portata 52W:
$1.01
$5.41
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Nome
Alterity Therapeutics Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Alterity Therapeutics Ltd Adr Borsa (ATHE) Ultime notizie
Alterity Therapeutics announces regulatory notice filing - Investing.com
Alterity Therapeutics announces regulatory notice filing - Investing.com India
ATHE’s Stock Market Adventure: -14.26% YTD Growth Amidst Volatility - The InvestChronicle
Alterity reports positive Phase 2 trial interim data - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
Alphabet stock cited by TD Cowen amid potential Wiz acquisition - Investing.com
Alterity Therapeutics announces trading halt By Investing.com - Investing.com
Avenue Supermarts stock target raised by Nuvama, still a Hold - Investing.com India
Wolfe Research keeps Peerperform rating on Goldman Sachs stock, notes mixed Q2 earnings - Investing.com India
RBC Capital sees growth potential in Bowhead Specialty shares - Investing.com
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar - GlobeNewswire Inc.
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study - GlobeNewswire Inc.
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review - GlobeNewswire Inc.
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report - GlobeNewswire Inc.
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia - GlobeNewswire Inc.
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Alterity Therapeutics announces trading halt By Investing.com - Investing.com India
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting - GlobeNewswire Inc.
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 - GlobeNewswire Inc.
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund - GlobeNewswire Inc.
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
ASX Health Winners December: Health stocks beat market, look ‘undervalued’ going into 2024 - Stockhead
Closing Bell: The ASX is slightly higher, but not much cooler on Monday - Stockhead
Biotech ‘to be worth $US4 trillion’ - Daily Telegraph
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
24 Stocks Moving in Friday's Pre-Market SessionAlterity Therapeutics (NASDAQ:ATHE) - Benzinga
ATHEAlterity Therapeutics Limited Latest Stock News & Market Updates - StockTitan
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
Check up: Enthusiasm rather than news is moving health stocks - Stockhead
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For An - Benzinga
54 Biggest Movers From YesterdayAcasti Pharma (NASDAQ:ACST), Alterity Therapeutics (NASDAQ:ATHE) - Benzinga
Alterity Therapeutics Ltd Adr Azioni (ATHE) Dati Finanziari
Non sono disponibili dati finanziari per Alterity Therapeutics Ltd Adr (ATHE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):